6-K
MDxHealth SA (MDXH)
UNITEDSTATES
SECURITIESAND EXCHANGE COMMISSION
Washington,D.C. 20549
FORM6-K
REPORTOF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE
SECURITIESEXCHANGE ACT OF 1934
Forthe month of August 2023
CommissionFile Number 001-40996
MDXHEALTHSA
(Translation of registrant’s name into English)
CAP Business Center
Zone Industrielle des Hauts-Sarts
4040 Herstal, Belgium
+32 4 257 70 21
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
MDXHEALTHSA
On August 9, 2023, MDxHealth SA (the “Company”) issued a press release, a copy of which is attached hereto as Exhibit 99.1.
Theinformation in the attached Exhibit 99.1 is being furnished and shall not be deemed “filed” for the purposes of Section 18of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of thatSection, nor shall it be deemed incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended,or the Exchange Act, except as otherwise set forth herein or as shall be expressly set forth by specific reference in such a filing.
| Exhibit No. | Description of Exhibit |
|---|---|
| 99.1 | Press Release, dated August 9, 2023 |
1
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| MDXHEALTH SA | |||
|---|---|---|---|
| Date:<br> August 10, 2023 | By: | /s/<br> Michael McGarrity | |
| Name: | Michael McGarrity | ||
| Title: | Chief Executive Officer |
2
Exhibit 99.1
NEWS RELEASE
9 AUGUST 2023, 4PM ET / 22:00 CET
Cigna Expands Commercial and Medicare AdvantageCoverage to Include Mdxhealth’s Select mdx for Prostate Cancer Test
Expansion of coverage with Cigna now includesfull menu of Company’s precision diagnostic prostate cancer tests, representing more than 15 million lives under coverage
IRVINE, CA, and HERSTAL,BELGIUM – August 9, 2023 – MDxHealth SA (NASDAQ/Euronext: MDXH), a commercial-stage precision diagnostics company, today announced that Cigna has expanded commercial and Medicare Advantage coverage to include the Company’s Select mdx for Prostate Cancer test. With the addition of Select mdx, Cigna will now provide insurance coverage across mdxhealth’s full menu of precision diagnostic cancer tests, including its Confirm mdx and Genomic Prostate Score (GPS) tests. Contracted coverage with Cigna for the Select mdx test is expected to take effect in Q4 of this year.
Michael K. McGarrity, CEO of MDxHealth, commented: “We are very pleased to announce this expansion of coverage with one of the largest health insurers in the United States, which will cover both commercial lives and Cigna’s substantial Medicare Advantage population. Expanding insurance coverage for our precision diagnostic tests remains a strategic priority at mdxhealth, and today’s announcement reflects our commitment to deliver our full menu of precision diagnostic prostate cancer solutions, all of which are included in the NCCN Guidelines, to help improve the diagnosis and management of prostate cancer.”
In the United States, prostate cancer is the most common and the second deadliest cancer for men. Nearly 280,000 prostate cancers are diagnosed annually in the U.S.^1^, and 69% of these cases are determined to be localized cancers that require either active surveillance or treatment decision. There are approximately 3 million prostate cancer screenings conducted in the U.S. which show elevated PSA results. Approximately 500,000 men undergo biopsies annually, but 60% of biopsies do not reveal cancer and may lead to increased complications and hospitalization. Moreover approximately 30% of cancer-negative biopsies are false negatives, meaning these patients actually have cancer.
About Select mdx
Select mdx for Prostate Cancer is a proprietary urine-based mRNA test that offers a non-invasive method to assess a patient’s risk for clinically significant prostate cancer. Select mdx helps identify men at increased risk for undetected aggressive, potentially lethal, prostate cancer who may benefit most from a prostate biopsy and earlier detection. The test delivers a negative predictive value of 95% for clinically significant disease, helping to reduce the need for MRI procedures and invasive prostate biopsies, thereby reducing healthcare costs. The test has been included in the Early Detection for Prostate Cancer National Comprehensive Cancer Network (NCCN) clinical guidelines.
About mdxhealth®
Mdxhealth is a commercial-stage precision diagnostics company that provides actionable molecular information to personalize patient diagnosis and treatment. The Company’s tests are based on proprietary genomic, epigenetic (methylation) and other molecular technologies and assist physicians with the diagnosis and prognosis of urologic cancers and other urologic diseases. The Company’s U.S. headquarters and laboratory operations are in Irvine, California, with additional laboratory operations in Plano, Texas. European headquarters are in Herstal, Belgium, with laboratory operations in Nijmegen, The Netherlands.
For more information, visit mdxhealth.com and follow us on social media at:
twitter.com/mdxhealth, facebook.com/mdxhealth and linkedin.com/company/mdxhealth.
| ^1^ | https://seer.cancer.gov/statfacts/html/prost.html |
|---|
For more information:
| mdxhealth<br><br> <br>info@mdxhealth.com |
|---|
| LifeSci Advisors (IR & PR)<br><br> <br>US: +1 949 271 9223<br><br> <br>ir@mdxhealth.com |
Forward-looking statements
This press release contains forward-lookingstatements and estimates with respect to the anticipated future performance of MDxHealth and the market in which it operates, all of whichinvolve certain risks and uncertainties. These statements are often, but are not always, made through the use of words or phrases suchas “potential,” “expect,” “will,” “goal,” “next,” “potential,”“aim,” “explore,” “forward,” “future,” and “believes” as well as similar expressions.Forward-looking statements contained in this release include, but are not limited to, statements regarding the acquisition of OncotypeDX® GPS prostate cancer business from Exact Sciences including statements regarding the anticipated benefits of the acquisition; statementsregarding expected future operating results; statements regarding product development efforts; and statements regarding our strategies,positioning, resources, capabilities and expectations for future events or performance. Such statements and estimates are based on assumptionsand assessments of known and unknown risks, uncertainties and other factors, which were deemed reasonable but may not prove to be correct.Actual events are difficult to predict, may depend upon factors that are beyond the company’s control, and may turn out to be materiallydifferent. Examples of forward-looking statements include, among others, statements we make regarding expected future operating results,product development efforts, our strategies, positioning, resources, capabilities and expectations for future events or performance. Importantfactors that could cause actual results, conditions and events to differ materially from those indicated in the forward-looking statementsinclude, among others, the following: uncertainties associated with the coronavirus (COVID-19) pandemic, including its possible effectson our operations, and the demand for our products; our ability to successfully and profitably market our products; the acceptance ofour products and services by healthcare providers; the willingness of health insurance companies and other payers to cover our productsand services and adequately reimburse us for such products and services; our ability to obtain and maintain regulatory approvals and complywith applicable regulations; the possibility that the anticipated benefits from our business acquisitions like our acquisition of theOncotype DX® GPS prostate cancer business will not be realized in full or at all or may take longer to realize than expected; andthe amount and nature of competition for our products and services. Other important risks and uncertainties are described in the RiskFactors sections of our most recent Annual Report on Form 20-F and in our other reports filed with the Securities and Exchange Commission.MDxHealth expressly disclaims any obligation to update any such forward-looking statements in this release to reflect any change in itsexpectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based unless requiredby law or regulation. This press release does not constitute an offer or invitation for the sale or purchase of securities or assets ofMDxHealth in any jurisdiction. No securities of MDxHealth may be offered or sold within the United States without registration under theU.S. Securities Act of 1933, as amended, or in compliance with an exemption therefrom, and in accordance with any applicable U.S. securitieslaws.
***NOTE:***The mdxhealth logo,mdxhealth, Confirm mdx, Select mdx, Resolve mdx, Genomic Prostate Score, GPS and Monitor mdx are trademarks or registered trademarks ofMDxHealth SA. The GPS test was formerly known as and is frequently referenced in guidelines, coverage policies, reimbursement decisions,manuscripts and other literature as Oncotype DX Prostate, Oncotype DX GPS, Oncotype DX Genomic Prostate Score, and Oncotype Dx ProstateCancer Assay, among others. The Oncotype DX trademark, and all other trademarks and service marks, are the property of their respectiveowners.